{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'subject with a positive NAb test at Week 72 (or PW) of the Follow-Up Period will continue to be', \"followed until the subject's value decreases or remains stable.\", 'Instructions for processing, handling, storing, and shipping of immunogenicity samples will be', 'detailed in a laboratory manual that will be provided to each site prior to site initiation.', '9.5.5.9 Data Safety Monitoring Board', 'The study will be monitored by a DSMB, which will advise the Sponsor regarding the', 'continuing safety of study subjects and potential subjects as well as continuing validity and', 'scientific merit of the trial. The details regarding frequency of meetings, members, and the safety', 'review criteria will be outlined in a separate DSMB Charter. ACI Clinical will manage the', 'logistics of the DSMB (Table 6.1).', '9.5.6 Appropriateness of Measurements', 'This study, which is a randomized, double-masked, placebo-controlled, parallel-group, multi-', 'center study, is designed according to standard principles for adequate and well-controlled', 'studies. The study population is well-defined and is consistent with the expected target', 'population for whom teprotumumab will be indicated (adult subjects previously diagnosed with', \"Graves' hyperthyroidism and with moderate-to-severe active TED).\", '9.5.7 Study Procedures', 'Subjects who provide informed consent and who meet all the entry criteria for participation in', 'this study will be randomized to treatment.', '9.5.7.1 Screening', 'Due to the large number of screening assessments, the Screening Visit may be completed in', 'more than one day. During the Screening Visit, potential study subjects will be informed fully', 'regarding the nature of the study and possible AEs, and will receive a copy of the ICF for review.', 'Potential study subjects must read the ICF and sign the document after the Investigator has', \"answered all questions to the study candidate's satisfaction. Further procedures can begin only\", 'after the ICF has been signed. The original signed ICF will be retained by the Investigator and a', 'copy will be given to the study subject.', 'Study candidates will be evaluated for study entry according to the stated inclusion and exclusion', 'criteria (Section 9.3). The Investigator will evaluate the results of all examinations, including', \"clinical laboratory tests, and will determine each candidate's suitability for the study. The\", 'Investigator must review the results of all Screening tests before determining that a candidate is', 'eligible for study drug treatment. The serum pregnancy test performed at Screening on all female', 'candidates of childbearing potential must be negative for those subjects to be eligible for', 'initiation of treatment. All screening procedures must be completed within 42 to 14 days prior to', 'Study Day 1 (i.e., the first day of administration of study drug). The following procedures will be', \"performed during Screening to establish each candidate's general health and eligibility for\", 'enrollment into the study:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 91 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Obtain signed, written informed consent and permission to use Protected Health', 'Information (in accordance with the Health Insurance Portability and Accountability Act', '[HIPAA]). Refusal to provide this permission excludes an individual from eligibility for', 'study participation. Record date informed consent was given and who conducted the', 'process on the appropriate source documentation.', \"Collect medical history, including tobacco use history and Graves' disease and treatment\", 'history. Ensure active TED is moderate to severe in intensity (non-sight threatening but', 'appreciable impact on daily life) with an onset of ophthalmic symptoms (as determined', 'by subject records) within 9 months prior to the projected Baseline Visit.', 'Determine study eligibility through review of the inclusion/exclusion criteria (see', 'Section 9.3)', 'Obtain demographics.', 'Enquire about prior medications (see Table 9.1 for restrictions regarding medications).', 'Obtain a serum sample from all females of childbearing potential for performance of a', 'pregnancy test.', 'Perform a physical examination, including measurements of height and weight.', 'Perform ophthalmic examination. Subjects who have decreased best-corrected visual', 'acuity due to optic neuropathy (defined by a decrease in vision of 2 lines on the Snellen', 'chart, new visual field defect, or color defect secondary to optic nerve involvement', 'within the last 6 months) are not eligible for enrollment.', 'Perform 12-lead ECG.', 'Record vital signs (blood pressure, pulse, respiration rate, and temperature). These', 'measurements will be performed according to standardized instructions. Record on the', 'appropriate source documentation.', 'Obtain blood samples for hematology and chemistry (including thyroid, glucose, and', 'HbA1c) analysis (see Section 9.5.5.7 for details concerning test results and study', 'participation).', 'Obtain a urine sample for urinalysis.', 'Complete the efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', 'Query subjects regarding signs and symptoms.', 'Contact IWRS to register the Screening Visit.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 92 of 117']\n\n###\n\n", "completion": "END"}